Get started
Work

Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma

Year: 2020
Type: article
Study design: Clinical Trial
Abstract: Hepatocellular carcinoma (HCC) is a common and deadly malignancy with few systemic therapy options. The RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) pathway is activated in approximately 50% to 60% of HCCs and represents a potential target for therapy. Selumetinib is an orally available inhibitor of MEK tyrosine kinase activity.
DOI: 10.17615/d1bm-nh04
Authors: Lush, Richard M., Strosberg, Jonathan R., Kazi, Aslamuzzaman, Learoyd, Maria, Sullivan, Daniel M., Bekaii-Saab, Tanios S., Goff, Laura W., Kauh, John Sae Wook, Sebti, Said M., Lee, Ruey-min, O'Neil, Bert H., Moore, Dominic T.
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: green
OpenAlex ID: W4300956024
FWCI:
Cites:
Cited by:
Related to: 10